Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Personalized medicine for non-small-cell lung cancer.

Kucherlapati R.

Oncology (Williston Park). 2010 Apr 30;24(5):399-400. No abstract available.

2.

Personalized medicine and inhibition of EGFR signaling in lung cancer.

Gazdar AF.

N Engl J Med. 2009 Sep 3;361(10):1018-20. doi: 10.1056/NEJMe0905763. Epub 2009 Aug 19. No abstract available.

3.

Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.

[No authors listed]

Technol Eval Cent Assess Program Exec Summ. 2011 Mar;25(6):1-5. No abstract available.

PMID:
21638942
4.

Targeting EGFR in non-small-cell lung cancer.

Doroshow JH.

N Engl J Med. 2005 Jul 14;353(2):200-2. No abstract available.

PMID:
16014890
5.

Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.

Kotsakis A, Georgoulias V.

Expert Opin Pharmacother. 2010 Oct;11(14):2363-89. doi: 10.1517/14656566.2010.498581. Review.

PMID:
20586711
6.
7.

[Personalized treatment in non-small cell lung cancer].

Campos-Parra AD, Cruz-Rico G, Arrieta O.

Rev Invest Clin. 2012 Jul-Aug;64(4):377-86. Review. Spanish. No abstract available.

PMID:
23227588
8.

EGFR testing in lung cancer is ready for prime time.

Hirsch FR, Bunn PA Jr.

Lancet Oncol. 2009 May;10(5):432-3. doi: 10.1016/S1470-2045(09)70110-X. No abstract available.

PMID:
19410185
9.
10.

Personalized medicine for non-small-cell lung cancer.

Mok TS, Zhou Q, Leung L, Loong HH.

Expert Rev Anticancer Ther. 2010 Oct;10(10):1601-11. doi: 10.1586/era.10.76. Review.

PMID:
20942631
11.

[Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].

Shi YK.

Zhonghua Zhong Liu Za Zhi. 2012 May;34(5):398-400. doi: 10. 3760/cma.j.issn.0253-3766.2012.05.019. Chinese. No abstract available.

PMID:
22883466
12.

Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?

Stinchcombe TE, Ramalingam SS.

Lancet Oncol. 2010 Jun;11(6):500-1. doi: 10.1016/S1470-2045(10)70120-0. Epub 2010 May 20. No abstract available.

PMID:
20493770
13.

Personalized medicine: Lung Cancer leads the way.

Parikh P, Puri T.

Indian J Cancer. 2013 Apr-Jun;50(2):77-9. doi: 10.4103/0019-509X.117005. No abstract available.

14.

The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation.

Langer CJ.

J Clin Oncol. 2009 Mar 20;27(9):1350-4. doi: 10.1200/JCO.2008.20.4859. Epub 2009 Feb 17. No abstract available.

15.

Unlocking the biological clues of lung cancer.

Hanna N.

J Thorac Oncol. 2008 Aug;3(8):809-10. doi: 10.1097/JTO.0b013e318183b0b7. No abstract available.

16.

[Resistant mechanism and treatment strategy of tyrosine kinase inhibitors].

Qiao J, Chen W.

Zhongguo Fei Ai Za Zhi. 2011 Oct;14(10):806-10. doi: 10.3779/j.issn.1009-3419.2011.10.07. Review. Chinese. No abstract available.

17.

Optimising therapy for EGFR-addicted NSCLC: just the start.

Govindan R, Subramanian J.

Lancet Oncol. 2012 Mar;13(3):216-7. doi: 10.1016/S1470-2045(12)70037-2. Epub 2012 Jan 26. No abstract available.

PMID:
22285167
18.

EGFR TKIs for advanced NSCLC: practical questions.

Perez-Soler R.

Oncology (Williston Park). 2010 Apr 30;24(5):400-1, 409. No abstract available.

19.

Personalized medicine in lung cancer: what we need to know.

Mok TS.

Nat Rev Clin Oncol. 2011 Aug 23;8(11):661-8. doi: 10.1038/nrclinonc.2011.126. Review.

PMID:
21862980
20.

EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer.

Sasaki H, Endo K, Mizuno K, Yano M, Fukai I, Yamakawa Y, Fujii Y.

Lung Cancer. 2006 Jan;51(1):135-6. Epub 2005 Nov 28. No abstract available.

PMID:
16314000
Items per page

Supplemental Content

Write to the Help Desk